Neuroscience
There has been a lot of web searching for information about Tysabri (natalizumab) [formerly Antegren] in the wake of the FDA approval last month for use in multiple sclerosis. A lot of searching has been by patients and concerned family members, clinicians and students, and those interested in the business applications.
I posted a couple of entries about the drug approval that are found in the November archives. I've been looking for a business commentary to note and found one earlier today:
In the business-world end of this, here is an interesting commentary from the 24th of November by a writer for TheStreet.com:
What Price Tysabri?
By Adam Feuerstein
Senior Writer, TheStreet.com
11/24/2004 8:00 AM EST
Read the opinion article
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab)
From the AP: Elan Shares Jump As Tysabri to Get Review By THE ASSOCIATED PRESS Published: November 18, 2005 Filed at 12:52 p.m. ET DUBLIN, Ireland (AP) -- Shares in Irish drug maker Elan Corp. PLC jumped Friday...
- Business World: Biogen Idec, Elan, Tysabri (natalizumab), And Multiple Sclerosis
From Bloomberg via the New York Times:Move to Reinstate Multiple Sclerosis Drug Published: September 21, 2005 By Bloomberg News Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) (cont.)
Additional information in follow-up to this morning's Boston Globe report, from Bloomberg:Elan, Biogen Decline on Report of New Tysabri Illness June 2 (Bloomberg) -- Shares of Elan Corp. and Biogen Idec Inc. tumbled after a fourth possible case of...
- More M.s. Drug Woes: Avonex And 683699
Biogen and F.D.A. Issue Drug Warning By ANDREW POLLACK The New York Times Published: March 17, 2005 Biogen Idec's multiple sclerosis drug Avonex might cause severe liver damage in rare cases, the company and the Food and Drug Administration said...
- Tysabri (natalizumab) Suspension
FOR IMMEDIATE RELEASE P05-07 February 28, 2005 Media Inquiries: 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Issues Public Health Advisory on Tysabri, a New Drug for MS The Food and Drug Administration (FDA) today issued a public health advisory...
Neuroscience
Business World: Biogen Idec, Elan, & Tysabri
There has been a lot of web searching for information about Tysabri (natalizumab) [formerly Antegren] in the wake of the FDA approval last month for use in multiple sclerosis. A lot of searching has been by patients and concerned family members, clinicians and students, and those interested in the business applications.
I posted a couple of entries about the drug approval that are found in the November archives. I've been looking for a business commentary to note and found one earlier today:
In the business-world end of this, here is an interesting commentary from the 24th of November by a writer for TheStreet.com:
What Price Tysabri?
By Adam Feuerstein
Senior Writer, TheStreet.com
11/24/2004 8:00 AM EST
Read the opinion article
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab)
From the AP: Elan Shares Jump As Tysabri to Get Review By THE ASSOCIATED PRESS Published: November 18, 2005 Filed at 12:52 p.m. ET DUBLIN, Ireland (AP) -- Shares in Irish drug maker Elan Corp. PLC jumped Friday...
- Business World: Biogen Idec, Elan, Tysabri (natalizumab), And Multiple Sclerosis
From Bloomberg via the New York Times:Move to Reinstate Multiple Sclerosis Drug Published: September 21, 2005 By Bloomberg News Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) (cont.)
Additional information in follow-up to this morning's Boston Globe report, from Bloomberg:Elan, Biogen Decline on Report of New Tysabri Illness June 2 (Bloomberg) -- Shares of Elan Corp. and Biogen Idec Inc. tumbled after a fourth possible case of...
- More M.s. Drug Woes: Avonex And 683699
Biogen and F.D.A. Issue Drug Warning By ANDREW POLLACK The New York Times Published: March 17, 2005 Biogen Idec's multiple sclerosis drug Avonex might cause severe liver damage in rare cases, the company and the Food and Drug Administration said...
- Tysabri (natalizumab) Suspension
FOR IMMEDIATE RELEASE P05-07 February 28, 2005 Media Inquiries: 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Issues Public Health Advisory on Tysabri, a New Drug for MS The Food and Drug Administration (FDA) today issued a public health advisory...